	Application No.	Applicant(s)
Notice of Allowability	10/524,609	JOSEPH JR. ET AL.
	Examiner	Art Unit
	SUE LIU	1639
The MAILING DATE of this communication appeal All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED in this app or other appropriate communication IGHTS. This application is subject to	olication. If not included will be mailed in due course. <b>THIS</b>
1. This communication is responsive to Remarks filed on 11/2	<u>2/09</u> .	
2. The allowed claim(s) is/are <u>1-3, 16, 20-42, 44 and 45</u> .		
3. ☐ Acknowledgment is made of a claim for foreign priority ur  a) ☐ All b) ☐ Some* c) ☐ None of the:  1. ☐ Certified copies of the priority documents have	e been received.	
<ul> <li>2.  Certified copies of the priority documents have been received in Application No</li> <li>3.  Copies of the certified copies of the priority documents have been received in this national stage application from the</li> </ul>		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the requirements
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	s Amendment / Comment or in the C	Office action of
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t		
6. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT		
Attachment(s)	5 Martine of Information	of and Annilland'an
<ol> <li>Notice of References Cited (PTO-892)</li> <li>D Notice of Draftperson's Patent Drawing Review (PTO-948)</li> </ol>	<ol> <li>5. ☐ Notice of Informal P</li> <li>6. ☑ Interview Summary</li> </ol>	···
	Paper No./Mail Dat	e <u>2/26/10</u> .
<ol> <li>Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date</li> </ol>	7. 🛛 Examiner's Amendr	nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit	8. 🔲 Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.	
/SUE LIU/		
Primary Examiner, Art Unit 1639		



Application No.

**EXAMINER'S AMENDMENT** 

1. An examiner's amendment to the record appears below. Should the changes and/or

additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR

1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the

payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with

Stephen J. Sand on 2/25/2010. (Also see the attached Interview Summary).

The application has been amended as follows:

Please cancel claims 17 and 43.

**Claim 16** is rewritten as follows:

"The method of claim 1, wherein said solution comprising said amount of guanidine

further comprises EDTA."

**Claim 21** is rewritten as follows:

"The method of claim 1, wherein said amount of guanidine is from about 0.5 mM to

about 1 mM."

**Claim 23** is rewritten as follows:

"The method of claim 1, wherein in step (d) the guanidine solution is added onto the ultrafiltration membrane surface prior to the addition of the sequencing reaction product onto the ultrafiltration membrane surface."

Page 3

Claim 24 is rewritten as follows:

"The method of claim 1, wherein in step (d) the guanidine solution is added onto the ultrafiltration membrane surface after to the addition of the sequencing reaction product onto the ultrafiltration membrane surface."

**Claim 42** is rewritten as follows:

"The method of claim 38, wherein said solution comprising said amount of guanidine further comprises EDTA."

## **Contact Information**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sue Liu whose telephone number is 571-272-5539. The examiner can normally be reached on M-F 9am-3pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached at 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/524,609 Page 4

Art Unit: 1639

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Sue Liu/ Primary Examiner, AU 1639

2/26/10